IDYA
IDEAYA Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IDYA
Ideaya Biosciences, Inc.
A company that developing oncology therapies for the treatment of cancer using molecular diagnostics
7000 Shoreline Court, Suite 350, South San Francisco, California 94080
--
IDEAYA Biosciences, Inc., headquartered in South San Francisco, California, was incorporated in Delaware in June 2015. The company is an oncology-focused precision medicine company dedicated to discovering and developing targeted therapies for patient populations selected using molecular diagnostics. Their approach combines the broad ability to identify and validate translated biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies they are developing. They are applying these capabilities to a variety of precision medicine, including direct targeting of carcinogenic pathways and synthetic lethality, which represents an emerging class of precision medicine targets.
Company Financials
EPS
IDYA has released its 2025 Q3 earnings. EPS was reported at 1.33, versus the expected -0.55, beating expectations. The chart below visualizes how IDYA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IDYA has released its 2025 Q3 earnings report, with revenue of 207.83M, reflecting a YoY change of NaN%, and net profit of 119.24M, showing a YoY change of 330.11%. The Sankey diagram below clearly presents IDYA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
